TETRAAMELIA SYNDROME 1; TETAMS1

Literature (3)

Literature for OMIM 273395: TETRAAMELIA SYNDROME 1; TETAMS1

Xenbase Articles:
(

Denotes literature images)

The Wnt-dependent signaling pathways as target in oncology drug discovery., Janssens N,Janicot M,Perera T, Invest New Drugs. July 1, 2006; 24(4):0167-6997.
RSPO2 inhibition of RNF43 and ZNRF3 governs limb development independently of LGR4/5/6., Szenker-Ravi E,Altunoglu U,Leushacke M,Khatoo M,Thi Tran H,Naert T,Noelanders R,Beneteau C,de Sousa SB,Karaman B,Başaran S,Tan TT,Vlaminck L,Nayak SS,Girisha KM,Le Caignec C,Soshnikova N,Vleminckx K,Vleminckx K,Barker N,Kayserili H,Bosso-Lefèvre C,Hajamohideen A,Latypova X,Yücel EB,Shukla A,Uyguner ZO,Reversade B, Nature. May 1, 2018; 557(7706):0143-5221.
Wnt/beta-catenin signaling: components, mechanisms, and diseases., MacDonald BT,Tamai K,He X, Dev Cell. July 1, 2009; 17(1):1878-1551.

The Wnt-dependent signaling pathways as target in oncology drug discovery., Janssens N,Janicot M,Perera T, Invest New Drugs. July 1, 2006; 24(4):0167-6997.

RSPO2 inhibition of RNF43 and ZNRF3 governs limb development independently of LGR4/5/6., Szenker-Ravi E,Altunoglu U,Leushacke M,Khatoo M,Thi Tran H,Naert T,Noelanders R,Beneteau C,de Sousa SB,Karaman B,Başaran S,Tan TT,Vlaminck L,Nayak SS,Girisha KM,Le Caignec C,Soshnikova N,Vleminckx K,Vleminckx K,Barker N,Kayserili H,Bosso-Lefèvre C,Hajamohideen A,Latypova X,Yücel EB,Shukla A,Uyguner ZO,Reversade B, Nature. May 1, 2018; 557(7706):0143-5221.

Wnt/beta-catenin signaling: components, mechanisms, and diseases., MacDonald BT,Tamai K,He X, Dev Cell. July 1, 2009; 17(1):1878-1551.